关税摩擦降温后，血制品的国产替代前景变了吗？

Group 1 - China has adjusted the tariff rate on imports from the US to 10%, suspending the previously implemented 24% rate for 90 days, significantly lower than the peak of 125% seen in April [1] - The adjustment in tariffs is expected to reduce the price pressure on imported blood products and slow down the expectations for domestic alternatives [1][2] - Major domestic blood product companies, including TianTan Bio, TaiBang Bio, and Hualan Bio, account for approximately 80% of the domestic plasma collection volume [1] Group 2 - The domestic market for human albumin, which constitutes about 70% of blood product usage, is heavily reliant on imports, with over 60% of the market share [2] - The price of imported human albumin products is currently higher than that of domestic products, but the tariff reduction to 10% will lessen the price advantage of imports [2][3] - The ongoing trade friction presents an opportunity for domestic products to penetrate hospital markets and adjust revenue structures, as hospitals may diversify their suppliers [3] Group 3 - The domestic blood product industry is currently in a downturn, with competition intensifying due to increased supply and price linkage effects [4] - Unlike the domestic market, where human albumin is predominant, international markets utilize immunoglobulin and coagulation factor products more extensively [5] - Domestic blood product companies face technological gaps compared to international leaders, limiting their product range and production capabilities [5]